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Identiﬁcation of alterations in the cellular composition of the human immune system is key to under-
standing the autoimmune process. Recently, a subset of FOXP3þ cells with low CD25 expression was
found to be increased in peripheral blood from systemic lupus erythematosus (SLE) patients, although its
functional signiﬁcance remains controversial. Here we ﬁnd in comparisons with healthy donors that the
frequency of FOXP3þ cells within CD127lowCD25low CD4þ T cells (here deﬁned as CD25lowFOXP3þ T cells)
is increased in patients affected by autoimmune disease of varying severity, from combined immuno-
deﬁciency with active autoimmunity, SLE to type 1 diabetes. We show that CD25lowFOXP3þ T cells share
phenotypic features resembling conventional CD127lowCD25highFOXP3þ Tregs, including demethylation
of the Treg-speciﬁc epigenetic control region in FOXP3, HELIOS expression, and lack of IL-2 production. As
compared to conventional Tregs, more CD25lowFOXP3þHELIOSþ T cells are in cell cycle (33.0% vs 20.7% Ki-
67þ; P ¼ 1.3  109) and express the late-stage inhibitory receptor PD-1 (67.2% vs 35.5%; P ¼ 4.0  1018),
while having reduced expression of the early-stage inhibitory receptor CTLA-4, as well as other Treg
markers, such as FOXP3 and CD15s. The number of CD25lowFOXP3þ T cells is correlated (P ¼ 3.1  107)
with the proportion of CD25highFOXP3þ T cells in cell cycle (Ki-67þ). These ﬁndings suggest that
CD25lowFOXP3þ T cells represent a subset of Tregs that are derived from CD25highFOXP3þ T cells, and are
a peripheral marker of recent Treg expansion in response to an autoimmune reaction in tissues.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
FOXP3þ regulatory T cells (Tregs) are produced in the thymus asr Human Genetics, Nufﬁeld
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Ltd. This is an open access article
a, et al., Cells with Treg-speciﬁ
oi.org/10.1016/j.jaut.2017.07.0a speciﬁc T cell lineage following high afﬁnity TCR engagement that
results in the demethylation of the Treg-speciﬁc demethylated re-
gion (TSDR) in FOXP3 and stable FOXP3 expression [1]. Following
emigration from the thymus and activation, naïve Tregs proliferate
and differentiate into memory Tregs that are actively recruited to
peripheral compartments to suppress immune responses against
self-antigen and maintain tissue integrity [2]. It is becoming
increasingly apparent that there is considerable heterogeneity in
memory Treg subsets in humans [3,4]. One major challenge for
studying human Tregs is that in general peripheral blood cells fromunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Baseline characteristics of study participants included in the association analyses.
Cohort N Age (years) Male N (%)
Median Range
SLE 34 36 20e72 2 (5.9%)
Healthy controls (CBR) - cohort 1 24 42 22e62 1 (4.2%)
Healthy controls (CBR) - cohort 2 112 49 26e78 30 (26.8%)
CID 7 23 13e45 5 (71.4%)
Healthy controls (CBR) 6 34 17e47 4 (66.7%)
T1D discovery cohort
T1D (D-GAP)a 49 13 6e34 32 (65.3%)
T1D (CBR)b 15 32 22e32 5 (33.3%)
T1D (combined) 64 14 6e42 37 (58.0%)
Unaffected Siblings (D-GAP)c 40 13 6e31 21 (52.5%)
Healthy Controls (CBR) 15 27 18e37 4 (26.7%)
Healthy controls (combined) 55 15 6e37 28 (45.9%)
T1D replication cohort
T1D (CBR) 15 37 17e52 5 (33.3%)
Healthy Controls (CBR) 15 37 22e47 4 (26.7%)
Baseline characteristics for the study participants stratiﬁed by the study cohorts.
a Newly diagnosed T1D patients (duration of disease  3 years) enrolled in the
Diabetes - Genes, Autoimmunity and Prevention (D-GAP) study.
b Long-standing adult T1D patients enrolled from the Cambridge BioResource
(CBR).
c First-degree sibling of a T1D patient, reporting no autoimmune disease and
determined to be negative for the following T1D-associated autoantibodies: IAA,
IA2, GAD and ZnT8. CID, Combined immunodeﬁciency; T1D, type 1 diabetes; SLE;
systemic lupus erythematosus.
R.C. Ferreira et al. / Journal of Autoimmunity xxx (2017) 1e122patients are more readily available, rather than the effector T cells
and Tregs present in the inﬂamed tissue and associated lymph
nodes. A better understanding of the composition of the Treg
compartment in peripheral blood is therefore needed to investigate
the potential contribution to disease made by Tregs and to identify
cellular alterations of the peripheral compartment associated with
the onset of pathogenic autoimmune destruction of the targeted
tissue.
Recently, a subset of FOXP3þ CD4þ T cells with low expression of
CD25 was reported to be increased in peripheral blood of autoim-
mune systemic lupus erythematosus (SLE) patients [5e9], a ﬁnding
that was later expanded to the peripheral blood of multiple scle-
rosis [10] and rheumatoid arthritis [11] patients. The frequency of
this cell subset has been demonstrated to be associated with
increased SLE disease activity in one study [7] but not in another
[5]. Nevertheless, in this second study the frequency of CD25low
FOXP3þ T cells was correlated with dsDNA antibodies levels [5,7]
suggesting that these cells may be directly pathogenic or bio-
markers of autoimmunity in these patients. However, their origin
and function in SLE patients and healthy individuals remain
ambiguous [12,13]. In the present study, we characterise these
CD127lowCD25lowFOXP3þ CD4þ T cells (henceforth designated as
CD25lowFOXP3þ cells), and demonstrate that they share phenotypic
features with Tregs, including demethylation of the FOXP3 TSDR
and constitutive expression of the transcription factor HELIOS in a
majority of the cells, and an inability to produce IL-2 compared to
FOXP3 Teffs. However, compared to conventional CD127low
CD25highFOXP3þ Tregs, CD25lowFOXP3þ cells showed increased
expression of activation and proliferationmarkers such as PD-1 and
Ki-67, and reduced expression of Treg-associated molecules,
including FOXP3 and CTLA-4. We suggest that these cells represent
the last stage of the natural life-cycle of TSDR-demethylated Tregs
in vivo and that chronic stimulation in the form of active autoim-
munity increases their prevalence.
2. Methods
2.1. Subjects
Study participants included 34 SLE patients recruited fromGuy's
and St Thomas' NHS Foundation Trust. All patients satisﬁed ACR SLE
classiﬁcation criteria and were allocated a disease activity using
SLEDAI-2K at the time of sampling. SLE patients were recruited
from a clinic inwhich the severity of diseasewas such that none the
patients were on high dose oral corticosteroids (>15 mg/day) or B-
cell depleting therapy. SLE patients were compared to a cohort of 24
age- and sex-matched healthy donors from the Cambridge Bio-
Resource (CBR). A second cohort of 112 healthy donors from the
CBR was used for the analysis of Ki-67 expression within the
assessed T cell subsets.
Combined immunodeﬁciency patients (CID; N ¼ 7) were
recruited from Cambridge University Hospitals and Papworth
Hospital NHS Foundation Trusts, and compared to six age- and sex-
matched healthy donors from the CBR. Patients were selected on
the presentation of immune inﬁltration in the lungs and active
autoimmunity in the absence of a known genetic cause, although
the clinical symptoms were consistent with those associated with
recently characterised CTLA4 germline mutations [14]. All CID pa-
tients were treated with immunoglobulin replacement therapy and
prophylactic antibiotics.
Adult long-standing T1D patients (N ¼ 15) and healthy controls
(HC; N ¼ 15) were recruited from the CBR. Newly diagnosed T1D
patients (ND; N ¼ 49) and unaffected siblings of other T1D pro-
bands (N ¼ 40) were collected from the JDRF DiabeteseGenes,
Autoimmunity and Prevention (D-GAP) study (http://paediatrics.Please cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.0medschl.cam.ac.uk/research/clinical-trials/). ND patients were
characterised as having been diagnosed with T1D less than two
years prior to their blood donation (with one exception of 42
months). Unaffected siblings were islet autoantibody-negative
(IAA, IA2, GAD and ZnT8), and were not related to any T1D pa-
tient included in this study. All donors were of white ethnicity and
all healthy controls and unaffected siblings were individuals
without autoimmune disease (self-reported). Baseline character-
istics for all participating subjects are summarised in Table 1.
2.2. Ethics
All samples and information were collected with written and
signed informed consent. The D-GAP study was approved by the
Royal Free Hospital & Medical School research ethics committee;
REC (08/H0720/25). Adult long-standing T1D patients and healthy
volunteers were enrolled in the CBR. The study was approved by
the local Peterborough and Fenland research ethics committee (05/
Q0106/20). Informed consent was obtained from CID patients,
parents, or both (R&D Ref: P01685, REC Ref: 12/WA/0148) and from
SLE patients (REC Ref: 07/H0718/49). The study conformed to the
Declaration of Helsinki and all local ethical requirements.
2.3. PBMC sample preparation
PBMCs were isolated by Ficoll gradient centrifugation and cry-
opreserved in 10% heat-inactivated human AB serum, as described
previously [15]. T1D patients and healthy controls were recruited
contemporaneously and samples were processed and stored by the
same investigators to prevent spurious ﬁndings caused by differ-
ential sample preparation.
Cryopreserved PBMCs (10  106 per donor) were thawed at
37 C and resuspended in X-VIVO (Lonza) þ 1% heat-inactivated,
ﬁltered human AB serum (Sigma). Cell viability following resusci-
tation was assessed in a subset of 40 donors using the Fixable
Viability Dye eFluor 780 (eBioscience) and was found to be
consistently very high (95.6%; min ¼ 86.8%, max ¼ 98.2%) for all
samples analysed in this study.c FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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To reduce the effects of experimental variation and other po-
tential covariates, PBMC samples were processed in batches of a
minimum of ten samples per day. T1D patients and healthy controls
were matched as closely as possible for age (within 5 year age-
bands), sex and time of sample preparation.
After thawing, PBMCs were resuspended in RPMI medium
(Gibco) supplementedwith 10% FBS, 2mM L-Glutamine and 100 mg/
mL Pen-Strep and cultured (106 PBMCs/well) in 24-well ﬂat-bottom
cell culture plate (BD). For cytokine production assays, cells were
initially rested for 30min at 37 C and then cultured in the presence
or absence of 5 ng/mL PMA, 100 ng/mL ionomycin and 0.67 ml/mL
Monensin GolgiStop (BD Biosciences) for 4 h at 37 C. For a subset of
66 donors, 106 cells were cultured with medium alone and 0.67 ml/
mL Monensin to determine background levels of cytokine pro-
duction in unstimulated cells.
2.5. Intracellular immunostainings
After activation, PBMCs were harvested, and stained with
Fixable Viability Dye eFluor 780 for 20 min at 4 C. Cells were then
stained with ﬂuorochrome-conjugated antibodies against surface
receptors (see Supplementary Table 1) for 1 h at 4 C. Fixation and
permeabilisation was performed using FOXP3 Fix/Perm Buffer Set
(BioLegend) and cells were then stained with intracellular anti-
bodies for 1 h at 4 C (see Supplementary Table 1). All experiments
were performed in an anonymised, blinded manner without prior
knowledge of disease state.
2.6. Flow cytometry
Immunostained samples were acquired using a BD Fortessa (BD
Biosciences) ﬂow cytometer with FACSDiva software (BD Bio-
sciences) and analysed using FlowJo (Tree Star, Inc.). Dead-cell
exclusion based on the Fixable Viability Dye was performed for
the intracellular immunostainings.
2.7. Analysis of the epigenetic demethylation proﬁle by next-
generation sequencing
Total PBMCs from seven healthy CBR donors (three males and
four females) were stainedwith ﬂuorophore-conjugated antibodies
(see Supplementary Table 1) and sorted using a BDAria Fusion ﬂow
cytometer (BD Biosciences). Methylation of the FOXP3 TSDR was
performed using a next-generation sequencing method, as
described previously [16].
2.8. Statistical analyses
Statistical analyses were performed using Prism software
(GraphPad) and Stata (www.stata.com). Association of the fre-
quency of CD25lowFOXP3þ T cells with T1D, SLE and CID was
calculated using two-tailed unpaired student's t-tests. The effects of
age, sex and time of collectionwere controlled by the experimental
design used in this study and, therefore, not included as additional
covariates. Given that most immune phenotypes showed moderate
to strong right skew that violated the assumption of normality, the
phenotypes were log-transformed before statistical testing.
Comparison of the expression of the interrogated immune
markers between CD127lowCD25lowFOXP3þ CD4þ T cells and: (i)
CD25highFOXP3þ, (ii) CD25highFOXP3 and (iii) CD25lowFOXP3
CD4þ T cells was performed within individuals using two-tailed
paired student's t-tests. The correlations between immune sub-
sets were calculated using linear regression analysis.Please cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.0To account for the issue of multiple testing we applied a con-
servative Bonferroni correction to determine the thresholds for
signiﬁcant results: (i) for the comparison of the frequency of
CD25lowFOXP3þ T cells between healthy donors and patients from
three different autoimmune diseases, we considered P
values < 0.0167 signiﬁcant (Bonferroni correction for three inde-
pendent tests); (ii) for the comparison of the ten assessed immune
markers between the CD25low and CD25high Treg subsets, we
considered P values < 0.005 signiﬁcant (Bonferroni correction for
ten independent tests).
3. Results
3.1. Frequency of CD25lowFOXP3þ T cells is increased in blood from
patients with active autoimmunity
To investigate the peripheral alterations in FOXP3þ T cell sub-
sets, we performed a detailed immunophenotyping characterisa-
tion of cryopreserved peripheral blood mononuclear cells (PBMCs)
of different cohorts of patients with autoimmune disease (sum-
marised in Table 1). Analysis of the ﬂow cytometry proﬁle of pa-
tients with systemic autoimmunity as compared to healthy donors
revealed that the frequency of FOXP3þ CD4þ T cells is highly
increased in CD127low cells of some patients. We found that among
SLE and CID patients with increased CD127low FOXP3-expressing
cells there is a notable loss of CD25 expression, which results in
an extremely high frequency of CD127lowCD25lowFOXP3þ cells
(Fig. 1A). These ﬁndings suggest that the frequency of FOXP3þ cells
in the CD127lowCD25low T cell subset (CD25lowFOXP3þ cells;
depicted in red in Fig. 1B) is increased as a result of an active
autoimmune response and could be a speciﬁc marker of Treg
activation. Given the lack of peripheral markers that reﬂect chronic
immune activation, we therefore decided to focus our analysis on
this population of CD25lowFOXP3þ cells, and investigate their fre-
quency in the peripheral blood of autoimmune patients.
Consistent with previous ﬁndings [7,8], we conﬁrmed that the
frequency of FOXP3þ cells among CD127lowCD25low T cells (gating
strategy Fig. 1B) was markedly increased in SLE patients (geometric
mean (GeoM) ¼ 13.5%) compared to age- and sex-matched healthy
controls (5.5%, P ¼ 2.1  105, N ¼ 24, Fig. 1C), which likely reﬂects
the systemic immune activation in SLE patients. In support of this
hypothesis, we also detected a high frequency of CD25lowFOXP3þ
cells in a small cohort of seven CID patients, characterised by severe
active autoimmunity compared to age- and sex-matched healthy
controls (12.1% and 4.0%, respectively, P ¼ 6.5  103; Fig. 1C).
We also found that the frequency of FOXP3þ cells among
CD127lowCD25low T cells was signiﬁcantly increased in T1D patients
(6.8%) compared to age- and sex-matched healthy controls (4.6%;
P ¼ 2.7  106; Fig. 1D). This association was also observed when
comparing the frequency of CD25lowFOXP3þ cells within total CD4þ
T cells (0.32% vs 0.23% in T1D patients and controls, respectively;
P¼ 1.1 103; Supplementary Fig. 1A). We replicated the ﬁnding of
increased FOXP3þ cells among CD127lowCD25low T cells in an in-
dependent cohort of 15 long-standing T1D patients (10.39%) and 15
age- and sex-matched healthy controls (6.3%; P ¼ 7.7  103;
Supplementary Fig. 1B). Furthermore, we noted that the increased
frequency of FOXP3þ cells was mainly restricted to the
CD127lowCD25low T cell subset, as we observed only a small
increased frequency of conventional CD127lowCD25highFOXP3þ
Tregs in T1D patients (5.6%) compared to healthy donors (4.8%;
P ¼ 8.0  103; Supplementary Fig. 2).
SLE disease activity index (SLEDAI) scores were available from
33 SLE patients evaluated for the frequency of
CD127lowCD25lowFOXP3þ Tregs. We noted that there was a trend
towards increased frequency of CD25lowFOXP3þ cells withc FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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Fig. 1. Frequency of CD25lowFOXP3þ cells is increased in patients with autoimmune disease. (A) Patterns of CD25 and FOXP3 expression among CD127low CD4þ T cells from
healthy donors and patients with autoimmune manifestations. (B) Gating strategy for the delineation of the T-cell subsets characterised in this study. Distribution of FOXP3þ cells
among: (i) CD127lowCD25high conventional Tregs (depicted in blue); and (ii) CD127lowCD25low T cells (depicted in red). The vertical dotted line represents the threshold for the
gating of FOXP3þ cells (histograms). (C, D) Scatter plots depict the frequency (geometric mean ± 95% CI) of FOXP3þ cells among CD127lowCD25low T cells in SLE patients (N ¼ 34
patients vs 24 healthy donors) and combined immunodeﬁciency patients with active autoimmunity (N ¼ 7 patients vs 6 healthy donors) (C); or in a cohort of T1D patients (N ¼ 62;
depicted by red circles) and healthy donors (N ¼ 54; depicted by black squares) (D). P values were calculated using two-tailed unpaired t-tests. P values < 0.0167 were considered
signiﬁcant (Bonferronni correction for the comparison in three different diseases). The initial CD4þ T cell gate (CD4 versus dead cell exclusion dye) was derived from a lymphocyte
gate (deﬁned on forward and side scatter) followed by single-cell discrimination. HC, healthy controls; T1D, type 1 diabetes patients; SLE, systemic lupus erythematosus patients;
CID, combined immunodeﬁciency patients. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
R.C. Ferreira et al. / Journal of Autoimmunity xxx (2017) 1e124increased SLEDAI at the time of sampling, although it did not reach
statistical signiﬁcance (Supplementary Fig. 3A). Previously a cor-
relation between disease activity and frequency of CD25lowFOXP3þ
cells was reported [7], whereas another study did not [5]. These
apparently conﬂicting results could be due to disease heteroge-
neity and relatively small sample sizes. Future longitudinal studies
assessing the frequency of CD25lowFOXP3þ cells in SLE and other
autoimmune patients with high levels of this Treg subset before
and following drug treatments will aid in resolving this uncer-
tainty. In the T1D patients, the frequency of CD25lowFOXP3þ cells
was not associated with duration of disease indicating that the
increased level of CD25low Tregs in T1D is not restricted to the time
of disease diagnosis (Supplementary Fig. 3B). The analysis was
restricted to the 49 recently diagnosed T1D patients (median 11
months, range 2e42 months) from the D-GAP cohort, which was a
much larger cohort and displayed a more homogeneous distri-
bution of time since diagnosis compared to the cohort of long-
standing diabetics.Please cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.03.2. CD25lowFOXP3þ cells are demethylated at the FOXP3 TSDR
In humans FOXP3 is not exclusively expressed in Tregs, but can
also be transiently up-regulated in activated Teffs. However, in
thymically-derived Tregs constitutive expression of FOXP3 is known
to require a demethylated TSDR [2]. To assess the TSDRmethylation
proﬁle of CD25lowFOXP3þ cells we sorted these cells from four
healthy donors, and compared the methylation of the TSDR in
CD25lowFOXP3þ cells, conventional CD25highFOXP3þ Tregs and the
respective FOXP3 subsets (Fig. 2A). We found that the majority of
CD25lowFOXP3þ cells were demethylated at the TSDR (Fig. 2B and
C). The epigenetic demethylation pattern in CD25lowFOXP3þ cells
was similar to CD25highFOXP3þ Tregs at all nine interrogated CpG
sites in the FOXP3 TSDR (mean ¼ 57.1% and 80.5% demethylation,
respectively; Fig. 2B); in contrast, <7% of CD25lowFOXP3 and
CD25highFOXP3 cells had demethylated TSDRs. These ﬁndings
indicate that the majority of CD25lowFOXP3þ cells are bona ﬁde
Tregs, and are not Teffs transiently upregulating FOXP3 expression
as a result of immune activation.c FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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Fig. 2. CD25lowFOXP3þ cells are demethylated at the FOXP3 Treg-speciﬁc demethylated region (TSDR). (A) Gating strategy for FACS sorting of four CD4þ T-cell subsets: (i)
CD127lowCD25lowFOXP3 (depicted in green), (ii) CD127lowCD25lowFOXP3þ (depicted in red), (iii) CD127lowCD25highFOXP3 (depicted in grey), and (iv) CD127lowCD25highFOXP3þ
(depicted in blue). (B) Frequency (mean ± SEM) of reads demethylated at eight or nine of the nine interrogated CpG sites in the FOXP3 TSDR. The data were obtained from sorted
cells from four independent healthy donors. (C) Graphic depicts the proportion of demethylated reads at the nine interrogated CpG sites from the FOXP3 TSDR in one illustrative
donor. Each horizontal line represents one sequencing read, with light green representing a methylated read (C) and dark green representing a demethylated read (T). Note that the
plot is representative of a male donor. For female donors, X-chromosome inactivation causes half of the reads to be methylated and a correction factor of two was applied to obtain
the frequency of demethylated reads. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
R.C. Ferreira et al. / Journal of Autoimmunity xxx (2017) 1e12 53.3. CD25lowFOXP3þ cells express the Treg-speciﬁc HELIOS
transcription factor and exhibit features of an activated phenotype
Having established that a majority of CD25lowFOXP3þ cells are
stably demethylated at the FOXP3 TSDR, we next performed a
detailed phenotypic characterisation of this subset by ﬂow
cytometry in 24 healthy adult donors to investigate phenotypic
similarities and differences between CD25lowFOXP3þ and classical
Tregs (CD25highFOXP3þ). One distinguishing feature of these cells
was the higher frequency of memory phenotype (CD45RA) cells
compared to their CD25highFOXP3þ counterparts (83.8% and 64.7%
CD45RA cells, respectively; P ¼ 2.0  1011; Fig. 3A). This differ-
ence was particularly noticeable among the younger cohort (me-
dian age ¼ 14 years) of 116 T1D patients and unaffected siblings
(76.9% and 43.4%, respectively; P¼ 1.2 1058; Fig. 3B), which have
a higher proportion of CD45RAþ naïve cells amongst theirPlease cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.0CD25highFOXP3þ conventional Tregs compared to adult donors,
suggesting that the majority of CD25lowFOXP3þ cells have respon-
ded previously to antigen, or have expanded in an antigen-
independent manner, following their emigration from the
thymus. Since the majority of CD25lowFOXP3þ cells are CD45RA,
we focused further analyses on memory FOXP3þ cells.
We found that an increased frequency of CD45RA
CD25lowFOXP3þ cells express the proliferation marker Ki-67
compared to their CD25highFOXP3þ counterparts (29.9% and
22.0%, respectively; P ¼ 2.7  107; Fig. 3C). In addition to Ki-67,
CD45RA CD25lowFOXP3þ cells were also characterised by a
marked increased frequency of PD-1þ cells compared to
CD25highFOXP3þ Tregs (65.1% and 38.3%, respectively;
P ¼ 1.7  1017; Fig. 3D), and had a frequency of PD-1þ cells more
similar to their CD25lowFOXP3 counterparts (67.2%; Fig. 3D).
Furthermore, we demonstrated that, similarly toc FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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Fig. 3. CD25lowFOXP3þ T cells display a memory phenotype. (A, B) Representative histograms and summary scatter plots depict the frequency (geometric mean ± 95% CI) of
CD45RAmemory T cells amongst the CD25lowFOXP3- and CD25lowFOXP3þ subsets in a population of 24 adult (median age ¼ 42 years) healthy donors (A) or in a population of 116
younger (median age ¼ 14 years) T1D patients (N ¼ 62) and healthy donors (N ¼ 54) (B). (C, D) Representative histograms and the frequency distribution (geometric mean ± 95% CI)
of Ki-67þ (C) and PD-1þ (D) cells in the CD45RA compartment of the four assessed immune subsets. P values were calculated using two-tailed paired t-tests comparing the
frequency of the assessed immune subsets from the same individual. P values < 0.005 were considered signiﬁcant (Bonferronni correction for the comparison of ten independent
immune markers between CD25lowFOXP3þ and CD25highFOXP3þ T cells). Gating strategy to delineate: (i) CD127lowCD25lowFOXP3 (highlighted in green), (ii)
CD127lowCD25lowFOXP3þ (highlighted in red), (iii) CD127lowCD25highFOXP3 (highlighted in grey), and (iv) CD127lowCD25highFOXP3þ (highlighted in blue) CD4þ T cells is depicted
in Fig. 2A. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
R.C. Ferreira et al. / Journal of Autoimmunity xxx (2017) 1e126CD25highFOXP3þ CD45RA memory Tregs, the majority of
CD25lowFOXP3þ CD45RA memory cells also express the tran-
scription factor HELIOS, although the proportion of HELIOSþ cells
was signiﬁcantly lower (51.1%) compared to CD25highFOXP3þ
CD45RA memory Tregs (77.8%; P ¼ 3.0  1012; Fig. 4A and B).
Consistent with the reduction in CD25 and HELIOS, CD25lowFOXP3þPlease cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.0cells also showed a signiﬁcantly lower expression of other classical
Treg markers compared to CD25highFOXP3þ Tregs, such as TIGIT
(65.1% vs 78.0%; P ¼ 3.7  108), CD15s (20.7% vs 33.5%;
P ¼ 5.8  1012) and most notably, CTLA-4 (60.0% vs 84.7%;
P ¼ 9.4  1011; Fig. 4A and B). Furthermore, we found that the
expression of FOXP3 was markedly lower in CD25lowFOXP3þ cellsc FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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Fig. 4. CD25lowFOXP3þ cells show reduced expression of several conventional Treg markers. (A) Representative histograms depict the distribution of the expression of the
conventional Treg markers HELIOS, TIGIT, CD15s and CTLA-4 amongst: (i) CD127lowCD25lowFOXP3 (highlighted in green), (ii) CD127lowCD25lowFOXP3þ (highlighted in red), (iii)
CD127lowCD25highFOXP3- (highlighted in grey), and (iv) CD127lowCD25highFOXP3þ (highlighted in blue) memory CD4þ T cells. (B) Scatter plots depict the distribution (geometric
mean ± 95% CI) of HELIOS (n ¼ 24), TIGIT (n ¼ 24), CD15s (n ¼ 24) and CTLA-4 (n ¼ 13) in the CD45RA compartment of the four assessed immune subsets. (C) Expression of FOXP3
(geometric mean ± 95% CI) was measured in the CD25lowFOXP3þ (depicted by red squares) and CD25highFOXP3þ (depicted by blue circles) subsets from 24 healthy donors. P values
were calculated using two-tailed paired t-tests comparing the assessed immunophenotypes between CD25lowFOXP3þ and the other three delineated subsets from the same in-
dividual. P values < 0.005 were considered signiﬁcant (Bonferronni correction for the comparison of ten independent immune markers between CD25lowFOXP3þ and
CD25highFOXP3þ T cells). MFI, mean ﬂuorescence intensity. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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tively, P ¼ 3.6  1011; Fig. 4C), suggesting that CD25lowFOXP3þ
cells show a decreased expression of classical Treg-associated
molecules.3.4. HELIOSþCD45RA CD25lowFOXP3þ cells are demethylated at
the FOXP3 TSDR to the same degree as conventional
HELIOSþCD45RA CD25high FOXP3þ Tregs
To further investigate the methylation proﬁle of FOXP3þ cells,
we next assessed the TSDR methylation in the HELIOSþ and HELI-
OS subsets in three additional healthy donors. In agreement with
their putative Treg lineage, we conﬁrmed that the HELIOSþ subsets
of both CD25lowFOXP3þ cells and conventional CD25highFOXP3þ
Tregs are virtually completely demethylated at the FOXP3 TSDR
(>95%; Fig. 5A). In contrast, the HELIOS subsets of CD25lowFOXP3þ
cells and conventional CD25highFOXP3þ Tregs contained a much
lower proportion of cells demethylated at the TSDR (21% and 64%,
respectively). Furthermore, to investigate if the FOXP3 methylation
status of CD25lowFOXP3þ cells was maintained in autoimmune
patients, we also assessed the TSDR methylation in three SLE pa-
tients recalled based on an increased frequency of CD25lowFOXP3þ
cells. Consistent with the results obtained from healthy donors, wePlease cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.0found that HELIOSþ CD25lowFOXP3þ cells were fully demethylated
at the FOXP3 TSDR (>95%; Supplementary Fig. 4).
Since HELIOS expression is highly enriched in FOXP3þ cells
demethylated at the TSDR, we examined other phenotypes within
the FOXP3þ cells stratiﬁed by HELIOS expression. CD25lowFOXP3þ
cells demethylated at the TSDR as deﬁned by HELIOS expression
had a higher proportion in cell cycle as compared to
CD25highFOXP3þ cells expressing HELIOS (33.0% and 20.7%,
respectively; Fig. 5B and C). In addition, the proportion of cells
expressing PD-1 and the per cell level of PD-1 were both increased
on CD25lowFOXP3þ demethylated at the TSDR as compared to their
CD25high counterparts (Fig. 5B and C). Expression of TIGIT, CTLA-4
and CD15s were also compared (Supplementary Figs. 5AeD) with
HELIOS stratiﬁcation revealing a high percentage (>89%) of TIGITþ
cells in both populations of demethylated FOXP3þ cells, but a
reduced number expressing CD15s and CTLA-4 in the
CD25lowFOXP3þ cells demethylated at the TSDR as compared to
their CD25high counterparts. High expression of CTLA-4was present
on CD25highFOXP3þHELIOS cells, a population with >50% of the
cells having a demethylated TSDR (Fig. 5A). Expression of FOXP3
was found to be signiﬁcantly higher within both conventional
CD25high Tregs (MFI > 2100) compared to CD25lowFOXP3þ HELIOSþ
T cells (MFI ¼ 1590), despite their demethylated TSDR. Notably, thec FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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Fig. 5. HELIOSþCD45RA CD25lowFOXP3þ cells are demethylated at TSDR as much as conventional HELIOSþCD45RA CD25highFOXP3þ Tregs. Frequency (mean ± SEM) of reads
demethylated at eight or nine of the nine interrogated CpG sites in the FOXP3 TSDR in CD45RA CD25lowFOXP3þ cells and CD45RA CD25highFOXP3þ Tregs stratiﬁed by the
expression of HELIOS. The data were obtained from sorted cells from three independent healthy donors.
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HELIOS T cells (MFI ¼ 952), which is consistent with their meth-
ylated TSDR (Supplementary Fig. 5E). Furthermore, analysis of
CD45RAþ expression revealed a signiﬁcantly lower frequency of
CD45RAþ cells within total CD25lowFOXP3þ HELIOSþ cells (4.7%)
compared to their CD25high counterparts (20.8%; P ¼ 2.0  1012;
Supplementary Fig. 5F). These data suggest that most of the
CD45RAþ cells observed within CD25lowFOXP3þ T cells are memory
effector T cells that have re-expressed CD45RA on their surface and
are characterised by being HELIOS and expressing lower levels of
FOXP3. Finally, since it was possible that the expansion of
CD25lowFOXP3þ HELIOS cells (most of which lack a demethylated
TSDR and might be activated effector cells) could have been
responsible for the increase of CD25lowFOXP3þ cells in autoimmune
patients (Fig. 1B and C), we examined the distribution of HELIOSþ
and HELIOS cells within the CD25lowFOXP3þ subset. We deter-
mined that HELIOSþ CD25lowFOXP3þ cells were increased in SLE,
CID and T1D patients as compared to their healthy control cohorts
(Supplementary Figs. 6A and B) similar to the ﬁndings with
CD25lowFOXP3þ cells (Fig. 1C and D) and that HELIOSþ cells
contributed signiﬁcantly to all cohorts examined (Supplementary
Figs. 6C and D).3.5. Low IL-2 production from HELIOSþCD45RA CD25lowFOXP3þ
cells
To characterise the function of HELIOSþCD45RAPlease cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.0CD25lowFOXP3þ cells, we assessed the production of two key cy-
tokines, IL-2 and IFN-g, in ten donors (ﬁve T1D patients and ﬁve
healthy controls) following in vitro stimulation (Fig. 6). Consistent
with their Treg-like phenotype, we found that both the HELIO-
SþCD45RA CD25lowFOXP3þ and CD25highFOXP3þ subsets, which
are highly demethylated at the TSDR (Fig. 5A), showed a low fre-
quency of IL-2þ (2.0% and 1.0%, respectively) and IFN-gþ cells (5.1%
and 1.4%, respectively; Fig. 6B and C). This was in marked contrast
with the HELIOSþCD25lowFOXP3 subset, which was found to
secrete signiﬁcantly higher levels of both IL-2 (21.3%;
P ¼ 2.8  105; Fig. 6B) and IFN-g (27.9%; P ¼ 1.1  103; Fig. 6C),
compared their FOXP3þ counterparts (2.0% and 5.1% for IL-2 and
IFN-g, respectively). In agreement with their regulatory phenotype,
we found a strong reduction of IL-2þ and IFN-gþ cells (2.0% and
5.1%, respectively) in HELIOSþCD45RA CD127lowCD25lowFOXP3þ
cells compared to conventional Teffs (59.8%, P ¼ 5.3  109 and
63.5%, P¼ 2.0 107 for IL-2þ and IFN-gþ cells, respectively; Fig. 6B
and C).
As compared to the HELIOSþ fraction, we found that a higher
portion of HELIOS CD45RA CD25lowFOXP3þ cells produced IFN-
g (Fig. 6A, Supplementary Fig. 7A). These ﬁndings are consistent
with a previous study, showing that HELIOSFOXP3þ T cells
produced IFN-g, and were increased among T1D patients [17].
Although we found no evidence for differential IFN-g production
in T1D patients compared to healthy controls among HELIOS
CD45RACD127lowCD25lowFOXP3þ cells, on a per cell basis
(Supplementary Fig. 7B), the higher frequency of thec FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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Fig. 6. HELIOSþCD45RA CD25lowFOXP3þ cells show impaired production of IL-2 and IFN-g. (A) Gating strategy to delineate the CD45RAHELIOSþ subset of: (i)
CD127lowCD25lowFOXP3þ (highlighted in red), (ii) CD127lowCD25highFOXP3þ (highlighted in blue), and (iii) CD127þCD25low/þFOXP3 HELIOS conventional (Conv) effector
(highlighted in black) subsets of CD4þ T cells. (B, C) Bar graphs depict the frequency (mean ± 95% CI) of IL-2þ and IFN-gþ cells in the CD45RAHELIOSþ compartment (or the
CD45RAHELIOS compartment in the case of the conventional effector T cells) of the ﬁve assessed immune subsets depicted in panel A. Cytokine production was assessed in one
single batch of ten donors. P values were calculated using two-tailed paired t-tests. P values < 0.005 were considered signiﬁcant (Bonferronni correction for the comparison of ten
independent immune markers between CD25lowFOXP3þ and CD25highFOXP3þ T cells). FACS gating plots depict data from one illustrative donor. *P < 0.05; **P < 0.01; ***P < 0.001.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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increase in the frequency of circulating FOXP3þ cells with the
capability to produce IFN-g following stimulation among total
CD4þ T cells (P ¼ 2.5  103; Supplementary Fig. 7C). These data
suggest that HELIOS CD45RA CD127lowCD25lowFOXP3þ cells
contributed to the increased frequency of IFN-gþ cells reported
among FOXP3þ cells from T1D patients [17].Please cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.03.6. CD25lowFOXP3þ T cells are highly correlated with proliferating
CD25highFOXP3þ Tregs
To investigate the possible relationship between CD25high and
CD25low FOXP3þHELIOSþ Tregs, we hypothesized that if CD25high
FOXP3þHELIOSþ Tregs are the precursors of the CD25low
FOXP3þHELIOSþ T cell subset, the numbers of CD25high Tregs in
cycle (Ki-67þ) and CD25low FOXP3þHELIOSþ T cells should bec FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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Fig. 7. Proliferating Ki-67þ CD25high FOXP3þHELIOSþ Tregs correlate with the frequencies of the CD25low and CD25highCD127low FOXP3þ HELIOSþ subsets. (A, B) Data shown
depict the correlation between the frequency within CD45RA CD4þ T cells of in-cycle (Ki-67þ) CD4þCD45RA CD127lowCD25high Tregs (FOXP3þHELIOSþ) and the frequency of
either CD25low FOXP3þHELIOSþ T cells (A) or conventional CD25high FOXP3þHELIOSþ Tregs (B). (C) Data shown depict the correlation between the frequencies of circulating
CD4þCD45RA CD25low FOXP3þHELIOSþ and CD25high FOXP3þHELIOSþ T cells. Frequencies of the assessed immune subsets were measured in PBMCs from healthy volunteers from
two independent cohorts: cohort 1 containing 24 donors (depicted in red) and cohort 2 containing 112 donors (depicted in black). The r2 values represent the coefﬁcient of
determination of the linear regression in the combined cohorts, and the P values correspond to the F statistic testing the null hypothesis that the slope of the linear regression
analysis is equal to 0. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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meostasis of Treg numbers such that as memory CD25high Tregs are
required to increase in peripheral compartments to respond to
inﬂammatory conditions, a higher Treg turnover would lead to
more CD25high Tregs moving into the CD25low compartment and
ultimately to cell death. We assessed the total numbers of CD45RA
Ki-67þ Tregs both in the cohort of 24 healthy volunteers (cohort 1)
and in an independent replication cohort (cohort 2) of 112 healthy
volunteers. We found that the frequency of CD45RA CD4þ Ki-67þ
CD25highFOXP3þHELIOSþ Tregs was signiﬁcantly correlated with
the frequency of CD25lowFOXP3þHELIOSþ T cells within total
memory CD4þ T cells (r2 ¼ 0.18, P ¼ 3.1  107; Fig. 7A). Similarly,
we observed a strong correlation between the numbers of in-cycle
Ki-67þ Tregs and the CD25highFOXP3þHELIOSþ Treg compartment
(r2 ¼ 0.46, P ¼ 1.2  1019; Fig. 7B), as well as a signiﬁcant corre-
lation between both the total CD25low and CD25high
FOXP3þHELIOSþ T cell compartments (r2 ¼ 0.15, P ¼ 3.9  106;
Fig. 7C). These observed correlations were very consistent within
both cohorts of healthy volunteers, and suggest that proliferation of
conventional CD25high FOXP3þHELIOSþ T cells is critical to promote
the homeostatic repopulation of the CD25high Treg subset, which is
maintained at a steady state frequency through the progression of a
proportion of CD25high Tregs to the CD25low FOXP3þHELIOSþ
compartment.
4. Discussion
The identiﬁcation of reliable biomarkers of disease activity has
been a major challenge of autoimmune diseases, particularly in
organ-speciﬁc diseases, such as T1D, where there is limited access
to the inﬂamed target tissues. In this study we characterised a
subset of FOXP3þ CD127lowCD25low CD4þ T cells, and show that it
could be a peripheral biomarker of a recent or chronic autoimmune
or cytokine-driven inﬂammatory reaction in the tissues. We
showed that in addition to SLE, where the increase of FOXP3þ
CD25low T cells has been observed in multiple studies [5e9], the
proportion of FOXP3þ cells in the CD127lowCD25low subset is
increased in CID and T1D patients. Although the frequency of
FOXP3þ cells in the CD127lowCD25low subset was compared in T1D
patients versus controls in one previous study with no difference
observed [13], we note that the number of participants was small:
10 healthy control individuals and 16 patients. In contrast, ZokaPlease cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.0et al. [18] observed that the proportion of CD25low cells among
FOXP3þCD4þ T cells is higher in T1D patients than in controls, a
phenotype consistent with our observations.
A major strength of this study is that we were able to use a
recently developed assay [16] to precisely assess the methylation
status of the FOXP3 TSDR of CD25lowFOXP3þ cells, a feature that was
lacking in the previous SLE studies [7,8] or studies of this subset
from healthy individuals [13]. This method provides a more quan-
titative assessment of the methylation pattern of the FOXP3 locus
[16] in the different immune subsets, which allowed us to
demonstrate that the epigenetic proﬁle of CD25lowFOXP3þ cells
was remarkably similar to conventional CD25high FOXP3þ Tregs
(57.1% and 80.5% demethylated at the TSDR, respectively). We went
on to deﬁne that this epigenetic similarity was caused primarily by
the TSDR methylation status of HELIOSþ cells: virtually all HELIOSþ
cells were found to be demethylated in both the CD25high and
CD25low FOXP3þ subsets. This ﬁnding is consistent with a previous
study assessing the FOXP3 TSDR methylation proﬁle in different
CD4þCD127low T-cell subsets discriminated by their expression of
FOXP3 and CD25 [19]. The majority of CD25lowFOXP3þ cells sorted
from synovial ﬂuid mononuclear cells of juvenile idiopathic
arthritis patients were shown to have a demethylated FOXP3 TSDR,
suggesting that this subset may be enriched at inﬂammatory sites
[19]. In the current study we also found that the proportion of cells
expressing TIGIT was elevated over 2-fold in both FOXP3þHELIOSþ
subsets as compared to their FOXP3þHELIOS counterparts. Stable
demethylation of the FOXP3 TSDR occurs in the thymus upon strong
T-cell receptor stimulation [1], therefore suggesting that CD25low
FOXP3þHELIOSþ cells are bona-ﬁde thymically-derived Tregs that
have lost the expression of CD25.
In further support of the hypothesis that CD25lowFOXP3þ
HELIOSþ T cells could be a subset of the classical FOXP3þ Treg
subset, these cells were unable to produce IL-2 following in vitro
activation. This ﬁnding was in contrast with the report by Yang et al
[8] that CD25lowFOXP3þ T cells from new-onset SLE patients were
able to secrete IL-2. However, we note that the IL-2 production
reported in Yang et al was much lower compared to
CD25highFOXP3 Teffs, and immune subsets were not stratiﬁed
based on the expression of CD127, CD45RA and HELIOS. It is
therefore likely that the residual production of IL-2 observed by
Yang et al in CD25lowFOXP3þ T cells was due primarily to HELIOS T
cells. In contrast, in our study we demonstrate that CD45RAc FOXP3 demethylation but low CD25 are prevalent in autoimmunity,
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to produce IL-2 as compared to CD127þCD25high CD45RA HELIO-
SFOXP3 Teffs. We also noted the overall heterogeneity in the
CD127low subset in regard to IL-2 and IFN-g secretion (Fig. 6). A
similar proportion of CD127low cells lacking both FOXP3 and HE-
LIOS expression secrete IL-2 and IFN-g as compared to their CD127þ
counterparts and are likely effector T cells. In healthy individuals
we observed that these putative effector cells are the largest
portion of the CD45RA CD25lowCD127low gate (Fig. 1B), consistent
with previous observations [13].
In addition to reduced levels of CD25, CD25low HELIOSþFOXP3þ
Tregs had lower expression of CTLA-4, CD15s and FOXP3 as
compared to CD25high HELIOSþFOXP3þ Tregs, suggesting that
CD25low Tregs could have decreased suppressive function. One
limitation of our study is that we are not able to directly assess the
suppressive capacity of CD25low HELIOSþFOXP3þ cells, as sorting on
the intracellular transcription factors precludes the use of these
cells for functional assays and surrogate surface markers are not yet
deﬁned. Also, as described above, the CD45RA CD25lowCD127low
gate has a high proportion of effector cells present, making the
results of suppression experiments using populations of cells gated
as CD25lowCD127low difﬁcult to interpret. Notably, despite the
cellular heterogeneity inherent in the CD25lowCD127low subset, two
studies did test the suppressive capacity of sorted CD25lowCD127low
CD4þ T cells [7,13]. Suppression of proliferation by Teffs was
mediated by CD25lowCD127low CD4þ T cells in both studies; how-
ever IFN-g secretion by Teffs was not suppressed in the one study
that examined this parameter [7]. The reduced suppression medi-
ated by CD25lowCD127low CD4þ Tcells could be due to the fact that a
larger proportion of effector cells are present in this subset as
compared with their CD25þ counterparts. Overall the observation
of suppression by CD25lowCD127low CD4þ T cells supports the
conclusion that the CD25low HELIOSþFOXP3þ Tregs present in the
heterogeneous CD25lowCD127low CD4þ T cell population are func-
tionally suppressive. Future studies are needed to unravel the
heterogeneity present in both the CD25low and CD25high
CD127lowCD4þ T cell subsets.
An increased frequency of CD25low FOXP3þ Tregs has now been
reported in a growing number autoimmune diseases, including SLE,
rheumatoid arthritis and multiple sclerosis [5e11]. In this study we
expanded this observation to patients with CID and T1D, suggesting
a common mechanism of CD25low FOXP3þ Tregs in countering
effector T cells as well as other cells promoting inﬂammation.
Further characterisation of CD25low FOXP3þ Tregs in longitudinal
studies correlating their frequencies with disease status and in
response to therapeutic interventions would help determine their
value as biomarkers. One study has shown in a small group of pa-
tients that treatment with glucocorticoids and cyclophosphamide
decreased the frequency of CD25low FOXP3þ Tregs in SLE patients
[5].
In our study we have provided a detailed phenotypic charac-
terisation of CD25low as compared to conventional CD25high
FOXP3þ Tregs. In contrast to the reduced expression of several
molecules that are abundant in CD25high FOXP3þ Tregs such as
CTLA-4, CD15s and FOXP3 itself, the frequency of cells expressing
PD-1 and Ki-67 in CD25low Tregs was higher than in conventional
CD25high Tregs, suggesting that the CD25low HELIOSþFOXP3þ pop-
ulation may represent the consequences of CD25high Tregs
attempting to suppress ongoing inﬂammatory responses in tissues.
The progression of CD25high Tregs to the CD25low Treg subset is
supported by our observation of the strong correlation between the
frequency of CD25high Tregs in cell cycle (Ki-67þ) with the number
of CD25low Tregs. The high proportion (15e40%) of memory
FOXP3þ Tregs in cycle is consistent with their shorter half-lives as
compared to other T cell subsets [20,21]. Thus, given the fact thatPlease cite this article in press as: R.C. Ferreira, et al., Cells with Treg-speciﬁ
Journal of Autoimmunity (2017), http://dx.doi.org/10.1016/j.jaut.2017.07.0Treg percentages normally remain constant in an individual
through time [21], and a high proportion of the cells are replicating,
Treg cell death must be a common outcome following cell division.
We propose that the decreased expression of CD25 on Tregs, most
likely caused by exposure to inﬂammatory conditions, causes less
responsiveness to IL-2, reduced expression of FOXP3 and other
Treg-associated molecules, and an increased probability of cell
death. Despite the reduced IL-2 responsiveness in CD25low Tregs, it
is possible that the Tregs remain functional and that the upregu-
lation of PD-1 could compensate for reductions in FOXP3 and CTLA-
4 levels [22]. Consistent with this hypothesis, previous studies have
reported that PD-1 is a critical inhibitory molecule that is upregu-
lated on T cells after activation [23e25]. In contrast, chronic PD-1
signaling within peripheral compartments has been reported to
lead to reduced STAT5 phosphorylation, decreased expression of
CD25, FOXP3 and CTLA-4, and decreased Treg suppressive function
[26e28]. Additional functional studies are required to resolve these
apparently contradictory mechanisms.
5. Conclusions
We hypothesize that the presence of a low frequency of CD25low
HELIOSþFOXP3þ cells in peripheral blood from healthy individuals
reﬂects a normal physiological mechanism tomaintain, genetically-
regulated, Treg levels. Their increased frequency in peripheral
blood from autoimmune patients, which is particularly noteworthy
in patients with chronic systemic inﬂammation, is indicative of an
inﬂammatory insult that drives the expansion of the Treg popula-
tion, which can be transient or chronic, in an attempt to regulate an
overt autoimmune Teff response. Given the paucity of reliable pe-
ripheral biomarkers of disease activity, our ﬁndings suggest that
the frequency of CD25low HELIOSþFOXP3þ Tregs could provide
valuable information about recent or ongoing tissue inﬂammation
and could have a clinical application for the stratiﬁcation of patients
with autoimmunity.
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